Form 4: Olema Pharmaceuticals Director Acquires Stock Options

Cynthia M. Butitta, a director of Olema Pharmaceuticals, acquired stock options for 23,000 shares on June 14, 2024.

Summary

• Cynthia M. Butitta, a director at Olema Pharmaceuticals, acquired stock options on June 14, 2024.
• The transaction involved stock options for 23,000 shares of common stock.
• The exercise price of the stock options is $12.36.
• The options vest in 12 equal monthly installments starting from June 14, 2024, contingent upon continuous service.
• Full vesting occurs at the next annual meeting if not fully vested before, subject to continued service.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects insider confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting schedule of the options.

Industry Context

This is a standard regulatory filing related to insider transactions. It's common for directors and officers to receive stock options as part of their compensation, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry, used to incentivize performance and align interests with shareholders.
• The vesting schedule of 12 months is fairly standard, although some companies may use longer vesting periods.
• The exercise price is set at $12.36, which may reflect the market price at the time of the grant.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates